ANTI-B-CELL THERAPY AT IMMUNE INFLAMMATORY RHEUMATIC DISEASES: EFFICACY AND TOLERABILITY IN 229 PATIENTS
Objective: to assess the efficacy and tolerability of Rituximab treatment in patients with serious immune inflammatory rheumatic diseases (IRD) like systemic lupus erythematosus (SLE), systemic sclerosis (SS), systemic vasculitis (SV), Sjogren syndrome (SjS), dermatomyositis/polymyositis (DM/PM).Sub...
Saved in:
Main Authors: | L. P. Ananieva, S. K. Soloviyov, T. V. Beketova, V. I. Vasiliev, O. A. Antelava, E. N. Aleksandrova, O. A. Koneva, M. E. Tsanyan, O. V. Desinova, O. A. Logvinenko, A. V. Volkov, A. N. Helkovskaya-Sergeeva, A. A. Novikov, A. A. Aleksankin, Ye. L. Nasonov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA PRESS LLC
2014-10-01
|
Series: | Научно-практическая ревматология |
Subjects: | |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/1982 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19)
by: E. L. Nasonov, et al.
Published: (2021-09-01) -
Rituximab for rheumatic diseases in children: Results of a retrospective study of the safety of therapy
by: M. I. Kaleda, et al.
Published: (2021-05-01) -
Pharmacotherapy of autoimmune rheumatic diseases – from monoclonal antibodies to CAR T cells: 20 years later
by: E. L. Nasonov, et al.
Published: (2024-06-01) -
RITUXIMAB TREATMENT FOR INTERSTITIAL LUNG INJURY IN SCLERODERMA SYSTEMATICA
by: Lidia Petrovna Ananieva, et al.
Published: (2013-12-01) -
Experience with Tixagevimab and Cilgavimab (Evusheld) in 86 rheumatic patients undergoing anti-B cell therapy with rituximab
by: T. V. Beketova, et al.
Published: (2023-04-01)